Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2026)

Recursion Pharmaceuticals' Current Assets history runs 7 years deep, the most recent figure standing at $709.6 million for Q1 2026.

• Quarterly Current Assets rose 21.47% year-over-year to $709.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $709.6 million (up 21.47% YoY) and the FY2025 annual result came in at $812.8 million, up 13.8% from the prior year.
• Current Assets was $709.6 million for Q1 2026 at Recursion Pharmaceuticals, down from $812.8 million in the prior quarter.
• Across five years, Current Assets topped out at $812.8 million in Q4 2025 and bottomed at $343.6 million in Q1 2024.
• A 5-year average of $555.9 million and a median of $546.0 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets jumped 179.26% — and 2024, when it plunged 30.18%.
• Recursion Pharmaceuticals' Current Assets stood at $569.8 million in 2022, then fell by 23.11% to $438.1 million in 2023, then soared by 63.02% to $714.3 million in 2024, then grew by 13.8% to $812.8 million in 2025, then fell by 12.71% to $709.6 million in 2026.
• Business Quant data shows RXRX's Current Assets at $709.6 million in Q1 2026, $812.8 million in Q4 2025, and $714.1 million in Q3 2025.